Emerging technologies allow for extensive diagnosis of the immune system’s role in disease prevention, progression and response to interventions. By combining next generation sequencing, machine learning, and bioinformatics, researchers are using Serimmune’s technology to generate deep immunome information provided by comprehensive antibody profiling to better understand clinical outcomes and allow for expedited diagnostic conclusions. This session will review available cutting-edge immune intelligence technology and present a case study that demonstrates the potential of this technology to improve clinical outcomes for a select disease and across a broad patient population.
Dr. Kamath is a founding scientist at Serimmune, Inc. Her expertise in therapeutic and diagnostic development has been essential to Serimmune’s Serum Epitope Repertoire Analysis (SERA) platform. SERA combines the power of bacterial display peptide library technology with next-generation sequencing and bioinformatics to profile antibody repertoires and identify and map antibody-based biomarkers of infections, autoimmunity and cancer. Once discovered, all the biomarkers can be assayed simultaneously from a single test, potentially reducing time to diagnosis or providing insights into the cause of undiagnosed disease. Prior to her work at Serimmune, Dr. Kamath worked on the development of cancer companion diagnostic and diagnostic assays at Agilent Technologies as well as modified therapeutic monoclonal antibodies (ProbodiesTM) at CytomX Therapeutics. She received her Ph.D. from University of California, Santa Barbara with an emphasis on cancer biology and therapy.
At Mymee, Dr. Lytle manages the coaching program, including all care delivery. She merges her education, clinical practice and research experience in the fields of naturopathic medicine, functional nutrition and chronic disease epidemiology to supervise all client consultations, develop coaching protocols, collect data and review RWE, participate in clinical trials and collaborate internally to build and execute program strategy. Dr. Lytle is a licensed naturopathic doctor, epidemiologist and nutrition specialist dedicated to preventing and reversing the epidemic of chronic disease. She earned her 4-year post grad ND from the Canadian College of Naturopathic Medicine and a Master's in Public Health (MPH) in Hamburg, Germany. In addition to 15 years of private practice, Millie is a published researcher and conference speaker.
Mymee and Serimmune Case Collaborations
Case analysis and outcomes will be presented on joint Mymee and Serimmune clients with particular focus on positive antibodies, client symptoms and diagnoses, and health related quality of life and disease improvement results.
Noah Nasser is Serimmune's Chief Executive Officer. With more than twenty-five years of experience in biotechnology, Noah brings a broad background in the development and commercialization of novel technology to advance human health. Noah joins Serimmune from San Diego biotechnology company, Human Longevity, Inc., a direct-to-consumer health screening organization combining proprietary imaging and genetic technologies, where he was chief commercial officer. Prior to Human Longevity, Noah was chief commercial officer at Counsyl, a market leading genetic testing laboratory focused on women's health applications, including non-invasive prenatal testing, expanded carrier screening and hereditary cancer screening. Noah led Counsyl's commercial team through its acquisition in 2018 by Myriad Genetics, Inc. He previously held senior leadership positions at San Diego-based biotechnology company AltheaDx, and San Carlos-based Verinata Health, a leader in non-invasive prenatal testing (NIPT), where he led his team through the company's acquisition by Illumina in 2013.
Applications of Functional Antibody Repertoire beyond Research
Serimmune has developed a novel technology for assessing personal immune response through antibody repertoires. We will describe the application of this technology in the clinical space for diagnosis of immune agents in diverse diseases and syndromes as well as how these data may lead to better health outcomes in the future.